---
title: "NKTR: Rezpegaldesleukin advanced to Phase 3, with robust cash reserves and narrowed Q2 net loss"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295843563.md"
description: "Advanced rezpegaldesleukin into Phase 3 trials, supported by strong cash reserves and a $373.8M public offering. Q2 net loss narrowed year-over-year, with increased R&D spending and decreased G&A costs. Cash runway extends into Q3 2028.Original document: Nektar Therapeutics [NKTR] SEC 8-K Current Report — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-13T20:35:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295843563.md)
  - [en](https://longbridge.com/en/news/295843563.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295843563.md)
generator: "portal-rs"
---

# NKTR: Rezpegaldesleukin advanced to Phase 3, with robust cash reserves and narrowed Q2 net loss

Advanced rezpegaldesleukin into Phase 3 trials, supported by strong cash reserves and a $373.8M public offering. Q2 net loss narrowed year-over-year, with increased R&D spending and decreased G&A costs. Cash runway extends into Q3 2028.

Original document: Nektar Therapeutics \[NKTR\] SEC 8-K Current Report — Aug. 13 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [NKTR.US](https://longbridge.com/en/quote/NKTR.US.md)

## Related News & Research

- [Nektar Therapeutics Rezpegaldesleukin Demonstrates Durability And Deepening Of Response Through One Year Of Treatment](https://longbridge.com/en/news/300677822.md)
- [NKTR: REZPEG rapidly improved clinical and molecular outcomes in moderate-to-severe atopic dermatitis](https://longbridge.com/en/news/300675523.md)
- [Nektar says Phase 3 ZENITH AD trial for rezpegaldesleukin expands into treatment-experienced patients](https://longbridge.com/en/news/300677883.md)
- [Nektar says rezpegaldesleukin shows early biomarker response in Phase 2b REZOLVE-AD atopic dermatitis study](https://longbridge.com/en/news/300588458.md)
- [Nektar says Phase 2b REZOLVE-AA trial posts new 6-month off-treatment rezpegaldesleukin data in severe alopecia areata](https://longbridge.com/en/news/300301661.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**